Abstract
Pyridoxine in doses of 250–500 mg daily by mouth was administered to 12 patients suffering from recurrent calcium oxalate renal calculi and idiopathic hyperoxaluria. This therapy decreased urinary oxalate excretion significantly (p<0.025) during up to 18 months of treatment. In that period eight patients showed no evidence of active stone disease; three showed slight increase in the size of their old stone(s) and one patient formed one new stone. None of these patients developed any significant complications of the therapy. These findings support the view that pyridoxine in pharmacological doses is useful in the control of elevated urinary oxalate excretion in patients with recurrent renal oxalate calculi.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Tiselius, H. G., Almgard, I. E.: The diurnal urinary excretion of oxalate and the effect of pyridoxine and ascorbate on oxalate excretion.Eur. Urol., 3, 4 (1977).
Revúsová, V., Gratzlová, J., Zvara, V.: The evaluation of some biochemical parameters in pyridoxine-treated calcium oxalate renal stone formers.Eur. Urol., 3, 32 (1977).
Gibbs, D. A., Watts, R. W. E.: The action of pyridoxine in primary hyperoxaluria.Clin. Sci., 38, 277 (1970).
Will, E. J., Bijvoet, O. L. M.: Primary oxalosis, clinical and biochemical response to high dose of pyridoxine therapy.Metabolism, 28, 542 (1979).
Smith, L. H., Williams, H. E.: Treatment of primary hyperoxaluria.Modern Treatment 4, 522 (1967).
Watts, R. W. E., Chalmers, R. A., Gibbs, D. A.: Studies on some possible biochemical treatment of primary hyperoxaluria.Quart. J. Med., 48, 259 (1979).
O’Regan, P. F. B., Constable, A. R., Harrison, A. R.: The management of the primary hyperoxaluric patient oxalate in human biochemistry and clinical pathology. In: Rose, A. R. (ed): Proceedings of an International Meeting, London 1979, pp. 209–219.
Prien, E. L., Gershoff, S. F.: Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi.J. Urol., 112, 509 (1974).
Harrison, A. R., Kasidas, G. P., Rose, G. A.: Hyperoxaluria and recurrent stone formation apparently cured by short courses of pyridoxine.Br. Med. J., 282, 2097 (1981).
Balcke, P., Schmidt, P., Zazgornik, J.: Pyridoxine therapy in patients with renal calcium oxalate calculi.Proc. EDTA, 20, 417 (1983).
Yendt, E. R., Cohanim, M.: Response to physiological dose of pyridoxine in type I primary hyperoxaluria.N. Engl. J. Med., 312, 953 (1985).
Hodgkins, Williams:Clinica Acta, 36, 127 (1972).
Williams, H. E., Smith, L. H. Jr.: Primary hyperoxaluria. In: Stanbury, J. B. (ed.): The Metabolic Basis of Inherited Disease. McGraw-Hill, New York 1983, pp. 204–228.
Andrus, S. B., Gershoff, S. N., Faragalla, F. F.: Production of calcium oxalate renal calculi in Vit B6 deficient rats.Lab. Invest., 9, 7 (1960).
Gershoff, S. N., Faragalla, F. F., Nelson, D. A.: Vit B6 deficiency and oxalate nephrocalcinosis in the cat.Am. J. Med., 27, 72 (1959).
Lyon, E. S., Borden, T. A., Ellis, J. E.: Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets.Invest. Urol., 4, 133 (1966).
Pyrah, L. N., Anderson, C. K., Hodgkinson, A.: A case of oxalate nephrocalcinosis and primary hyperoxaluria.Br. J. Urol., 31, 235 (1959).
Moore, C. A., Bunce, G. E.: Reduction in frequency of renal calculus formation by oral magnesium administration.Invest. Urol., 2, 7 (1964).
Pinto, B., Bernshtm, J.: Diethylaminoethanol-cellulose in the treatment of absorptive hyperoxaluria.J. Urol., 119, 630 (1978).
Solomons, C. C., Goodman, S. I., Riley, C. M.: Calcium carbimide in the treatment of primary hyperoxalauria.N. Engl. J. Med., 276, 267 (1967).
King, J. S. Jr., Wainer, A.: Glyoxalate metabolism in normal stone forming humans and the effect of allopurinol therapy.Exp. Biol. Med., 128, 1162 (1968).
Rose, D. P.: The influence of oestrogens on tryptophan metabolism in man.Clin. Sci., 31, 265 (1966).
Gibbs, D. A., Watts, R. W. E.: Biochemical studies on the treatment of primary hyperoxaluria.Arch. Dis. Child., 42, 505 (1967).
Dent, C. E., Stamp, T. C. B.: Treatment of primary hyperoxaluria.Arch. Dis. Child., 45, 735 (1970).
Daniel, R. A., Michels, R., Aisen, P.: Familial hyperoxaluria.Am. J. Med., 29, 820 (1961).
Schaumburg, H., Kaplan, J., Windebank, A.: Sensory neuropathy from pyridoxine abuse, a new megavitamin syndrome.N. Engl. J. Med., 309, 445 (1983).
Berger, A., Schaumburg, H. H.: More on neuropathy from pyridoxine abuse.N. Engl. J. Med., 310, 986 (1984).
Mitwalli, A. H., Blair, G., Oreopoulos, D. G.: Safety of intermediate doses of pyridoxine.Can. Med. Assoc. J., 131, 14 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mitwalli, A., Ayiomamitis, A., Grass, L. et al. Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. International Urology and Nephrology 20, 353–359 (1988). https://doi.org/10.1007/BF02549567
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02549567